Dan Peer is a Professor and the Director of the Laboratory of Precision NanoMedicine at Tel Aviv University (TAU). He is also the Chair of Tel Aviv University Cancer Biology Research Center; the biggest Cancer Center in Israel that includes 17 affiliated hospitals and the Founding and Managing Director of the SPARK program of Translational Medicine at TAU.

Prof. Peer’s work was among the first to demonstrate systemic delivery of RNA molecules using targeted nanocarriers to the immune system and he pioneered the use of RNA interference (RNAi) and modified mRNA for in vivo validation of new drug targets within the immune system that has enormous implications in cancer and inflammation.

Prof. Peer has more than 90 pending and granted patents. Some of them have been licensed to several pharmaceutical companies and one is currently under registration (as a new drug in inflammatory bowel disease). In addition, based on his work, four spin-off companies were generated aiming to bring innovative personalized medicine into clinical practice.  

Prof. Peer is now studying the use of cannabinoids (both natural and synthetic) in Cancer, Non alcoholic liver diseases and in inflammatory bowel diseases going all the way from the lab into the clinic.

Prof. Peer is a scientific advisory board member in more than 10 companies, four of them are public companies. He is a past President of the Israeli Chapter of the Controlled Release Society, and a Member of the Israel Young Academy of Science.